iProtics is a groundbreaking company dedicated to revolutionizing the treatment of cancer and auto-immune disorders. With a deep understanding of proteasomes, crucial protein-regulating complexes, iProtics aims to develop selective immunoproteasome inhibitors that target disease-causing cells while preserving the integrity of healthy tissues. Unlike current clinical drugs that indiscriminately affect both cancerous and somatic cells, iProtics' innovative approach offers a paradigm shift in therapy.
Founded by a skilled team encompassing expertise in design, synthesis, drug development, and business strategies, iProtics builds upon the remarkable discoveries made by the esteemed Overkleeft group at Leiden University.
Company Details
- Founded
- -
- Address
- Leiden, Nl
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- HQ
- Leiden
Iprotics Questions
Iprotics's LinkedIn profile is https://nl.linkedin.com/company/iprotics
Iprotics's industry is
Biotechnology Research
Iprotics's top competitors are
Genlumina,
Geheco,
Passionfruit,
Uniiq - Finance For The Future,
Catherinn Bv,
Bionomic,
Spatialise,
Igp - Occupational Health,
Xs Innovations,
Hypersoniq.
Iprotics's categories are Biotechnology Research
Iprotics's founding year is 2023
